INS and Hypoglycemia: Although the impact of changing an insulin product on parameters such as glycemic control and hypoglycemia is best assessed in a clinical trial setting, the short deviation in plasma insulin concentrations from steady state (~ 3 days) demonstrated by these PK simulations suggest that switching from Gla-100 to Gla-300 while increasing the daily dose should be relatively trouble free.